Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335140 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
A Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00335140: Clinical Trial Phase 2 study, sponsored by Eastern Cooperative Oncology Group.
NCT00335140 is a Phase 2 study that was terminated before completion, run by Eastern Cooperative Oncology Group. The registered enrollment target is 26 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00335140, a Phase 2 study, was terminated before completion, sponsored by Eastern Cooperative Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with primary central nervous system (CNS) lymphoma.
Primary Outcome
Assessed by the ECOG-ACRIN data manager based upon local review of images and data sent by the local sites. Treatment response was determined by calculating the sum of the maximal cross section in 2 separate axes using enhancing lesion(s) on CT or MRI imaging. The same imaging modality was to be used throughout assessment. Complete response was defined as the disappearance of all contrast enhancing tumor size on CT or MRI, patient was off all glucocorticoids, and resolution of all meningeal and
Interventions
- DRUG Leucovorin
- DRUG Dexamethasone
- BIOLOGICAL Rituximab
- DRUG Cytarabine
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-08-23 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Why NCT00335140 stopped before completion
NCT00335140 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 5 interventions - of which Leucovorin is the first listed.
NCT00335140 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00335140 about?
NCT00335140 is a clinical study titled "Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma". RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leu...
What is the current status of trial NCT00335140?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2007-08-23. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00335140?
The interventions under investigation include: Leucovorin (DRUG), Dexamethasone (DRUG), Rituximab (BIOLOGICAL), Cytarabine (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00335140?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00335140's enrollment target sits among peer trials
26 1708th of 2000 higher than 282 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI